Trial Profile
Phase I Study of Sorafenib, Pemetrexed, and Cisplatin for the Treatment of Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Jun 2018
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Cisplatin; Pemetrexed
- Indications Advanced breast cancer; Colon cancer; Head and neck cancer; Lung cancer; Mesothelioma; Pancreatic cancer; Prostate cancer; Sarcoma; Solid tumours
- Focus Adverse reactions
- 05 Jun 2018 Results (n=16) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 30 Nov 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 30 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.